CN103301088B - 一种鸡胚多糖胶囊制剂及其制备方法 - Google Patents
一种鸡胚多糖胶囊制剂及其制备方法 Download PDFInfo
- Publication number
- CN103301088B CN103301088B CN201310276172.7A CN201310276172A CN103301088B CN 103301088 B CN103301088 B CN 103301088B CN 201310276172 A CN201310276172 A CN 201310276172A CN 103301088 B CN103301088 B CN 103301088B
- Authority
- CN
- China
- Prior art keywords
- chick embryo
- preparation
- polysaccharide
- embryo polysaccharide
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003837 chick embryo Anatomy 0.000 title claims abstract description 124
- 150000004676 glycans Chemical class 0.000 title claims abstract description 113
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 113
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 113
- 239000002775 capsule Substances 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 81
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000008187 granular material Substances 0.000 claims description 59
- 238000002156 mixing Methods 0.000 claims description 34
- 239000000047 product Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 19
- 238000004090 dissolution Methods 0.000 claims description 19
- 235000019698 starch Nutrition 0.000 claims description 19
- 239000008107 starch Substances 0.000 claims description 19
- 239000007779 soft material Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 238000003860 storage Methods 0.000 claims description 16
- 241000287828 Gallus gallus Species 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 15
- 238000007689 inspection Methods 0.000 claims description 15
- 210000001161 mammalian embryo Anatomy 0.000 claims description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000004806 packaging method and process Methods 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- 229910002027 silica gel Inorganic materials 0.000 claims description 13
- 229960001866 silicon dioxide Drugs 0.000 claims description 13
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 12
- 229910052782 aluminium Inorganic materials 0.000 claims description 12
- 239000002274 desiccant Substances 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 229920001903 high density polyethylene Polymers 0.000 claims description 12
- 239000004700 high-density polyethylene Substances 0.000 claims description 12
- 238000011068 loading method Methods 0.000 claims description 12
- 229920003023 plastic Polymers 0.000 claims description 12
- 239000004033 plastic Substances 0.000 claims description 12
- 239000002985 plastic film Substances 0.000 claims description 12
- 229920006255 plastic film Polymers 0.000 claims description 12
- 230000001476 alcoholic effect Effects 0.000 claims description 11
- 239000002002 slurry Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 10
- 230000033228 biological regulation Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- BIGPRXCJEDHCLP-UHFFFAOYSA-N ammonium bisulfate Chemical compound [NH4+].OS([O-])(=O)=O BIGPRXCJEDHCLP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 5
- 235000013330 chicken meat Nutrition 0.000 claims description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000005374 membrane filtration Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 10
- 238000005516 engineering process Methods 0.000 abstract description 8
- 239000002671 adjuvant Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000011230 binding agent Substances 0.000 abstract description 4
- 239000000945 filler Substances 0.000 abstract description 4
- 239000000314 lubricant Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 abstract 1
- 239000003005 anticarcinogenic agent Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001133 acceleration Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- 241000230452 Cyclothone braueri Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310276172.7A CN103301088B (zh) | 2013-07-03 | 2013-07-03 | 一种鸡胚多糖胶囊制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310276172.7A CN103301088B (zh) | 2013-07-03 | 2013-07-03 | 一种鸡胚多糖胶囊制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103301088A CN103301088A (zh) | 2013-09-18 |
CN103301088B true CN103301088B (zh) | 2016-02-10 |
Family
ID=49127098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310276172.7A Expired - Fee Related CN103301088B (zh) | 2013-07-03 | 2013-07-03 | 一种鸡胚多糖胶囊制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103301088B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104546793B (zh) * | 2014-05-06 | 2015-08-12 | 山东中医药大学 | 一种降糖鸡腿蘑胶囊制剂及其制备方法 |
CN106994121B (zh) * | 2016-01-26 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 一种用于治疗癌症的药物组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985330A (en) * | 1996-08-05 | 1999-11-16 | Coastside Bio Resources | Inhibition of angiogenesis by sea cucumber fractions |
CN1748713A (zh) * | 2005-09-13 | 2006-03-22 | 陈正跃 | 鸡胚胎素的制备方法 |
CN102028199A (zh) * | 2010-11-08 | 2011-04-27 | 河南科技大学 | 鸡胚蛋保健胶囊及其加工工艺 |
CN103145867A (zh) * | 2013-03-22 | 2013-06-12 | 乔民 | 一种抗肿瘤生物多糖 |
CN103142528A (zh) * | 2013-03-28 | 2013-06-12 | 乔民 | 一种鸡胚多糖的片剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20010779A1 (it) * | 2001-04-12 | 2002-10-12 | Giorgio Zoppetti | Uso di polisaccaridi batterici solfati atti all'inibizione dell'angiogenesi |
-
2013
- 2013-07-03 CN CN201310276172.7A patent/CN103301088B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985330A (en) * | 1996-08-05 | 1999-11-16 | Coastside Bio Resources | Inhibition of angiogenesis by sea cucumber fractions |
CN1748713A (zh) * | 2005-09-13 | 2006-03-22 | 陈正跃 | 鸡胚胎素的制备方法 |
CN102028199A (zh) * | 2010-11-08 | 2011-04-27 | 河南科技大学 | 鸡胚蛋保健胶囊及其加工工艺 |
CN103145867A (zh) * | 2013-03-22 | 2013-06-12 | 乔民 | 一种抗肿瘤生物多糖 |
CN103142528A (zh) * | 2013-03-28 | 2013-06-12 | 乔民 | 一种鸡胚多糖的片剂 |
Also Published As
Publication number | Publication date |
---|---|
CN103301088A (zh) | 2013-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104274390B (zh) | 一种噻吗洛尔长效透皮制剂及其在血管瘤中的应用 | |
JP7060631B2 (ja) | 腫瘍を治療および/または予防する薬物の調製におけるイソバレリルスピラマイシンi、iiおよび/またはiiiの応用、ならびに薬物 | |
CN103301088B (zh) | 一种鸡胚多糖胶囊制剂及其制备方法 | |
WO2006079288A1 (fr) | Emploi de lysozyme humaine dans la préparation de produits cosmétiques contre l'acné | |
CN103768063A (zh) | 一种盐酸莫西沙星药物组合物及其制备方法 | |
WO2021219113A1 (zh) | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 | |
CN105753719B (zh) | 一种盐酸曲恩汀化合物 | |
CN103655514B (zh) | 一种高分子植物复合材料及其制备方法 | |
CN103494780B (zh) | 一种注射用加米霉素组合物冻干粉及制备方法 | |
CN104435078B (zh) | 一种组合物及其应用和制剂 | |
CN108670956A (zh) | 一种阿莫西林可溶性粉及其制备方法 | |
CN109276553A (zh) | 二甲胺含笑内酯富马酸盐制剂、其制备方法和用途 | |
CN104490942B (zh) | 桑黄作为治疗肿瘤药物的应用 | |
WO2021219112A1 (zh) | 异戊酰螺旋霉素类化合物或其组合物在制备治疗脓毒症疾病药物中的应用 | |
CN104546793B (zh) | 一种降糖鸡腿蘑胶囊制剂及其制备方法 | |
CN103142528B (zh) | 一种鸡胚多糖的片剂 | |
CN1814048A (zh) | 裸花紫珠中药液体胶囊及其制备方法和质量控制方法 | |
CN102626411A (zh) | 丙泊酚与阿片类镇痛剂的药物组合物及其应用 | |
CN105412039A (zh) | 一种琥珀酸呋罗曲坦控释片及其制备方法 | |
WO2019141256A1 (zh) | 可利霉素或其活性成分的用途 | |
CN109646392A (zh) | 一种含克林霉素磷酸酯的凝胶剂及其制备工艺 | |
CN107213119B (zh) | 一种他米巴罗汀口服固体制剂、其制备方法和用途 | |
CN103330686B (zh) | 一种鸡胚多糖注射用冻干粉针剂及其制备方法 | |
CN108498565B (zh) | 一种复方扶芳藤软胶囊及其制备方法 | |
CN101057868A (zh) | 治疗骨质疏松等疾病的中药制剂及制法和质控方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
DD01 | Delivery of document by public notice |
Addressee: BEIJING HONGZU BIOTECHNOLOGY CO.,LTD. Document name: Notification to Go Through Formalities of Registration |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20151225 Address after: 100078 Beijing City, Fengtai District Fangzhuang Park moon Vista A building block 1805 Applicant after: Jin Lianying Applicant after: Wang Xiaoshan Applicant after: Liu Zhanwei Address before: 102600 Beijing Keyuan Daxing District Huangcun Industrial Development Zone Road No. 18 Applicant before: BEIJING HONGZU BIOTECHNOLOGY CO.,LTD. |
|
DD01 | Delivery of document by public notice |
Addressee: Guo Yanling Document name: Notification of Passing Examination on Formalities |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160210 Termination date: 20180703 |